Valued at 9,400,000€, Bionure is overfunding on Capital Cell, raising more than 975,422€ from over 210 investors for 9.27% equity for its neuroprotector and myelin regenerator drug which treat Multiple Sclerosis. Bionure is a biotech-based company that is developing a new drug for the treatment of multiple sclerosis, a… Read More
Crowdfund Insider is the leading news and information web site covering the emerging global industry of disruptive finance including investment crowdfunding, Blockchain peer-to-peer / marketplace lending and other forms of Fintech.
